Summary & Overview
HCPCS Level II J2793: Rilonacept Injection, 1 mg
HCPCS Level II code J2793 denotes a per-milligram billing unit for injection of rilonacept, a targeted biologic therapy used in specific inflammatory conditions. Nationally, accurate reporting of drug J-codes like J2793 is essential for reimbursement, utilization tracking, and pharmacovigilance given high per-unit costs and site-of-care variability. This publication examines coverage patterns and payer approaches for rilonacept injection across major payers.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payer coverage considerations, typical sites of service where J2793 is billed, common billing and documentation practices, and operational benchmarks relevant to infusion and outpatient administration. The report also outlines clinical context for use and highlights where data is available versus where input was not provided.
The content is organized to help billing managers, revenue cycle professionals, and policy analysts understand how J2793 is used in practice, what to expect from major payers, and which operational factors influence billing and payment for injectable biologic therapies.
Billing Code Overview
HCPCS Level II code J2793 represents the drug injection rilonacept, billed per 1 mg. This code is used to report administration of the biologic agent rilonacept when supplied for injection.
-
Service type: Drug administration (injectable biologic)
-
Typical site of service: Infusion clinic, outpatient hospital department, physician office, or other outpatient settings where injected biologic therapies are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with recurrent pericarditis or another autoinflammatory condition for which interleukin-1 blockade with rilonacept is indicated. The patient presents to an outpatient infusion clinic or specialty injection suite for administration of a subcutaneous injection of J2793 (rilonacept, 1 mg). The workflow includes verification of order and indication, pre-administration assessment (vital signs, review of allergies and concurrent medications, screening for active infection), preparation of the single-dose syringe or vial per manufacturer guidance, site selection and aseptic technique for a subcutaneous injection, administration, and a 15–30 minute post-injection observation period for immediate adverse reactions. Documentation includes the medication name and HCPCS code J2793, total milligrams administered, lot number and expiration date, injection site, any modifier if applicable, the administering clinician’s taxonomy and credentials, and a procedure note including patient tolerance and any adverse events. Billing follows payor-specific rules for physician-administered drugs, and may require reporting of appropriate modifiers such as JW for discarded drug, or site-of-service modifiers if administered in an outpatient hospital or ambulatory surgical center setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|